Free Trial
NASDAQ:MGRM

Monogram Orthopaedics Q4 2023 Earnings Report

Monogram Orthopaedics logo
$6.22 +0.11 (+1.80%)
Closing price 10/6/2025 07:06 PM Eastern
Extended Trading
$6.22 0.00 (0.00%)
As of 10/6/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monogram Orthopaedics EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Monogram Orthopaedics Revenue Results

Actual Revenue
$0.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Monogram Orthopaedics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 15, 2024
Conference Call Time
8:30AM ET

Upcoming Earnings

Monogram Orthopaedics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Tuesday, November 18, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Monogram Orthopaedics Earnings Headlines

Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
Monogram Orthopaedics Faces Merger Review Delay
Monogram Orthopaedics Delays 10-Q Filing
See More Monogram Orthopaedics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monogram Orthopaedics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monogram Orthopaedics and other key companies, straight to your email.

About Monogram Orthopaedics

Monogram Orthopaedics (NASDAQ:MGRM), traded on Nasdaq under the ticker MGRM, is a commercial-stage medical device company focused on developing and delivering personalized knee replacement solutions. The company’s mission centers on improving patient outcomes in knee arthroplasty by leveraging advanced design and manufacturing methods to tailor implants and instrumentation to each individual’s unique anatomy.

At the core of Monogram’s offering is the Monogram Knee System, which combines proprietary imaging software with additive manufacturing techniques to produce patient-specific implants and surgical instruments. Preoperative MRI or CT scans are used to create a three-dimensional model of the patient’s knee, allowing the system to optimize implant geometry, alignment guides, and cutting blocks. This customized approach aims to enhance implant fit, reduce surgical times, and potentially improve post-operative function and comfort.

Founded in 2018 and headquartered in Menlo Park, California, Monogram Orthopaedics has secured FDA 510(k) clearance for its partial knee replacement system and completed its first commercial cases in leading U.S. orthopedic centers. The company continues to expand its commercial footprint across the United States, with plans to pursue additional regulatory approvals and market entry in select international regions.

View Monogram Orthopaedics Profile

More Earnings Resources from MarketBeat